Skip to Content
Lee G Wilke, MD, FACS

Surgical Services

Contact Dr. Wilke


(608) 263-1164

600 Highland Avenue
Box 7375 Clinical Science Center
Madison, WI 53792

Lee G Wilke, MD, FACS

Interim Chair, Divisions of General Surgery
Director, UW Health Breast Center
Professor, Division of Surgical Oncology


  • MD, Duke University, Durham, NC, 1993
  • Residency in Surgery, University of Michigan, Ann Arbor, Michigan, 1993-2000
  • ACS Resident Research Fellow in Immunotherapy, University of Michigan, Ann Arbor, MI 1996-1998

Clinical Specialties

Dr. Wilke is certified by the American Board of Surgery and specializes in benign and malignant diseases of the breast; sentinel lymph-node mapping; neoadjuvant therapy for breast cancer; and oncoplastic breast surgery.

Dr. Wilke provides a wide range of services including Axillary Lymph Node Dissection, Core Needle Biopsy, Lumpectomy or Partial Mastectomy, Modified Radical Mastectomy, Needle-localized Biopsy, Needle-localized Excision, Sentinel Lymph Node Biopsy, Simple Mastectomy, and Skin-sparing and/or Nipple-sparing Mastectomy.

Research Interests

Dr. Wilke’s principal research interest is in clinical trials seeking novel methods of treating patients with breast cancer. Dr. Wilke is a member of the Commission on Cancer. She is also a collaborator on multiple grants and trials evaluating novel treatments for breast cancer.

Active Clinical Trials

Recent Publications
  • Cancer Survivorship Care Plan Utilization and Impact on Clinical Decision-Making at Point-of-Care Visits with Primary Care: Results from an Engineering, Primary Care, and Oncology Collaborative for Survivorship Health.
    Donohue S, Haine JE, Li Z, Feldstein DA, Micek M, Trowbridge ER, Kamnetz SA, Sosman JM, Wilke LG, Sesto ME, Tevaarwerk AJ
    J Cancer Educ 2017 Nov 02.
    [PubMed ID: 29098650]
    More Information
  • The Impact of a Primary Care Education Program Regarding Cancer Survivorship Care Plans: Results from an Engineering, Primary Care, and Oncology Collaborative for Survivorship Health.
    Donohue S, Haine JE, Li Z, Trowbridge ER, Kamnetz SA, Feldstein DA, Sosman JM, Wilke LG, Sesto ME, Tevaarwerk AJ
    J Cancer Educ 2017 Sep 20.
    [PubMed ID: 28932992]
    More Information
  • A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.
    Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ
    Clin. Cancer Res. 2017 Nov 15; 23(22):6823-6832.
    [PubMed ID: 28874413]
    More Information
  • Socioeconomic Factors Associated with Post-Mastectomy Immediate Reconstruction in a Contemporary Cohort of Breast Cancer Survivors.
    Schumacher JR, Taylor LJ, Tucholka JL, Poore S, Eggen A, Steiman J, Wilke LG, Greenberg CC, Neuman HB
    Ann. Surg. Oncol. 2017 Aug 01.
    [PubMed ID: 28766209]
    More Information
  • Mammography Screening: Gaps in Patient's and Physician's Needs for Shared Decision-Making.
    DuBenske LL, Schrager S, McDowell H, Wilke LG, Trentham-Dietz A, Burnside ES
    Breast J 2017 Mar; 23(2):210-214.
    [PubMed ID: 28252231, PMC ID: 5516643]
    More Information
  • Breast Cancer Survivor Advocacy at a University Hospital: Development of a Peer Support Program with Evaluation by Patients, Advocates, and Clinicians.
    Mirrielees JA, Breckheimer KR, White TA, Denure DA, Schroeder MM, Gaines ME, Wilke LG, Tevaarwerk AJ
    J Cancer Educ 2017 Mar; 32(1):97-104.
    [PubMed ID: 26477478, PMC ID: 4837082]
    More Information
  • Fewer Reoperations After Lumpectomy for Breast Cancer with Neoadjuvant Rather than Adjuvant Chemotherapy: A Report from the National Cancer Database.
    Landercasper J, Bennie B, Parsons BM, Dietrich LL, Greenberg CC, Wilke LG, Linebarger JH
    Ann. Surg. Oncol. 2017 Jun; 24(6):1507-1515.
    [PubMed ID: 28062931, PMC ID: 5413581]
    More Information
  • Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy.
    Hunt KK, Euhus DM, Boughey JC, Chagpar AB, Feldman SM, Hansen NM, Kulkarni SA, McCready DR, Mamounas EP, Wilke LG, Van Zee KJ, Morrow M
    Ann. Surg. Oncol. 2017 Feb; 24(2):375-397.
    [PubMed ID: 27933411]
    More Information
  • Reexcision Surgery for Breast Cancer: An Analysis of the American Society of Breast Surgeons (ASBrS) Mastery(SM) Database Following the SSO-ASTRO "No Ink on Tumor" Guidelines.
    Schulman AM, Mirrielees JA, Leverson G, Landercasper J, Greenberg C, Wilke LG
    Ann. Surg. Oncol. 2017 Jan; 24(1):52-58.
    [PubMed ID: 27581607]
    More Information
  • Contralateral Prophylactic Mastectomy Consensus Statement from the American Society of Breast Surgeons: Additional Considerations and a Framework for Shared Decision Making.
    Boughey JC, Attai DJ, Chen SL, Cody HS, Dietz JR, Feldman SM, Greenberg CC, Kass RB, Landercasper J, Lemaine V, MacNeill F, Margenthaler JA, Song DH, Staley AC, Wilke LG, Willey SC, Yao KA
    Ann. Surg. Oncol. 2016 Oct; 23(10):3106-11.
    [PubMed ID: 27469118, PMC ID: 4999472]
    More Information Copyright © 2017 The Board of Regents of the University of Wisconsin System